Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 10/20 | 0.38 |
| ▸ | HRH1 | P35367 | 10/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094059 | 0.91 | HRH2 (0.42) | HRH2HRH1HRH3KCNH2CYP19A1 | |
| SCHEMBL2958755 | 0.88 | KCNH2 (0.42) | HRH2HRH1HRH3KCNH2CYP19A1 | |
| SCHEMBL5965605 | 0.87 | HRH2 (0.38) | HRH2HRH1HRH3KCNH2HTR7 | |
| SCHEMBL7028285 | 0.83 | CYP19A1 (0.38) | HRH2HRH1HRH3KCNH2CYP19A1 | |
| SCHEMBL7035866 | 0.82 | HRH3 (0.49) | HRH2HRH1HRH3 | |
| SCHEMBL7243646 | 0.81 | HRH3 (0.38) | HRH2HRH1HRH3KCNH2CYP19A1 | |
| SCHEMBL6996965 | 0.80 | SIGMAR1 (0.41) | HRH2HRH1HRH3CYP19A1HTR7 | |
| SCHEMBL7028521 | 0.80 | EGLN2 (0.40) | HRH2HRH1HRH3MEN1 | |
| SCHEMBL6093675 | 0.79 | HRH2 (0.40) | HRH2HRH1HRH3 | |
| SCHEMBL6995882 | 0.78 | DRD3 (0.52) | HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1301510-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004446-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | HRH2 229/4885HRH1 322/4885HRH3 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.